Taylor Sandison - 15 Mar 2024 Form 4 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role
Chief Medical Officer
Signature
/s/ Shane Ward, Attorney-in-Fact
Issuer symbol
CDTX
Transactions as of
15 Mar 2024
Net transactions value
$0
Form type
4
Filing time
20 Mar 2024, 18:47:07 UTC
Previous filing
12 Mar 2024
Next filing
13 Sep 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDTX Common Stock Award $0 +128,750 +37% $0.000000 475,845 15 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDTX Employee Stock Option (right to buy) Award $0 +235,500 $0.000000 235,500 15 Mar 2024 Common Stock 235,500 $0.6849 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents time-based Restricted Stock Units (RSUs) granted on March 15, 2024. All RSUs vest in three equal annual installments, with 1/3 vesting on each of March 10, 2025, 2026, and 2027, subject to continuous service through each such vesting date.
F2 The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 15, 2024.